Entity family

Browse institutions

Universities, hospitals, research centres, networks, and public bodies. Examples include universities, NHS trusts, research networks.

1articles mentioning institutions

2institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: EORTC-1508GCG ×

EORTC-1508GCG

This institution is selected. Its supporting articles are shown below.

EORTC-1508GCG1

Articles mentioning EORTC-1508GCG

1 articles · page 1 of 1

500 Biomarker identification of early response and resistance to combinatorial anti-angiogenic and immune-checkpoint blockade therapy in the recurrent ovarian cancer setting

jitc · abstract · 2025-11-04 · 2 matching annotations

90.7%

EORTC-1508GCG atezolizumab bevacizumab atezolizumab-containing High-grade serous ovarian cancer aspirin PROC low-dose aspirin PD-L1 blockade platinum-resistant ovarian cancer+1 more

…elial barrier, potentially synergizing with PD-L1 blockade. The EORTC-1508GCG phase II trial evaluated atezolizumab (anti-PD-L1), bevacizumab…